What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).
As goes SLE, bullous disease typically affects women, especially those of African descent.
The NY Times reports that a recent survey of drug use indicates that daily consumption of marijuana among young adults nearly doubled in the last decade. This is coupled with growing mainstream acceptance of cannabis and hallucinogenic compounds.
Dr. John Cush RheumNow
3 years 3 months ago
Voltage-gated Na channels (NaV) in nociceptive neurons may lead to pain stimuli in #OA. Tamoxifen metabolites inhibit NaVs & was studied in animal model of OA, showing analgesic effects equal to CBD and lidocaine. https://t.co/1Tu9No8ZnT https://t.co/JKoxiAh15O
Dr. John Cush RheumNow
3 years 3 months ago
Weight Loss Slows Knee OA Progression
Declines in body mass index (BMI) were linked with slower worsening of knee osteoarthritis (OA), according to data from three large longitudinal cohort studies.
https://t.co/dxvqueq7B5 https://t.co/Odx73kOeaO
Dr. John Cush RheumNow
3 years 3 months ago
Charcot (neuropathic) arthropathy of elbow due to Syringomyelia - review of 50 pts. Median age 45 yrs, 2/3 isolated elbow arthritis; other joints: shoulder > wrist > MCPs/IPs. 2/3 had Chiari malformations, sensory/motor deficits, or ulnar neuropathy https://t.co/KjOpAKxs6i https://t.co/87Asmlzq3K
Dr. John Cush RheumNow
3 years 3 months ago
Matched cohort study of survival in 1139 incident systemic sclerosis pts & 5613 controls. W/ median F/U of 5-6 yrs, deaths were 268 vs 554. 5 Yr survival was lower 79.8% vs 92.9% (10yr survival 67.7% vs 84.8%). SSc had higher 1 yrs mortality (HR 3.7) https://t.co/rGlTWUVVMU https://t.co/XeKnjldgye
Dr. John Cush RheumNow
3 years 3 months ago
Review of VTE risk with JAK inhibitors
- Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk factors, VTE 0.35/100PY
- Baricitinib: IR of DVT/PE was 0.5/100PY
- Filgotinib: 200mg VTEs 0.2/100PY
Most VTE occured in LT extension of RCT https://t.co/xeX4wj4cWU https://t.co/CJV2h9zO9a
Dr. John Cush RheumNow
3 years 3 months ago
Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis
A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.
https://t.co/9rFGMLtV5Z https://t.co/3L4mid8i0n
A recent meta-analysis suggests a bidirectional association between rheumatoid arthritis (RA) and depression. Finding RA patients with depression yields an 80% increased mortality risk.
Anti-cytokine therapies represents a potential alternative for the treatment of depression.
Analysis of 11 cohort studies included 39,130 RA patients, 550,782 patients with depression and 7,802,230 controls.
Declines in body mass index (BMI) were linked with slower worsening of knee osteoarthritis (OA), according to data from three large longitudinal cohort studies.
Dr. John Cush RheumNow
3 years 3 months ago
Anti-rheumatics drug market accounted for $57 billion in sales in 2018 and is expected to reach nearly $72 billion by 2026, registering a CAGR of 2.9% from 2019 to 2026. https://t.co/X77cx5QM4G https://t.co/eNCvemksWK
Dr. John Cush RheumNow
3 years 3 months ago
Look-alike Humans identified by facial recognition algorithms identify found to share common genetic sequences such as face trait variants. DNA methylation & microbiome profiles only contribute modestly to human likeness. https://t.co/2KjFAmhPvi https://t.co/RBjHObv2RU
Dr. John Cush RheumNow
3 years 3 months ago
73 #RA pregnancies w/ live births. 88% were in remission/low disease before conception. RA flares occurred in 37% (in 1st &2nd trim). Preterm assoc w/ Flares; flares more likely if bDMARD D/C @ +Preg test (55% w/ flare vs. 30% w/o flare, p 0.03, OR 2.9) https://t.co/hVtUuX3lfr https://t.co/bFbyQZbcim
Dr. John Cush RheumNow
3 years 3 months ago
Chinese study of 215 Bx proven #SLE pts - all rx w/ IV CTX+steroids. Responders were given either AZA or leflunomide. Renal outcomes were same w/ LEF or AZA as maintenance. Flares (16% vs 18%), Time to flare (16 v 14 mos), AE, proteinuria https://t.co/Ad7Ec4OPco https://t.co/NoKAgiMKrK
Dr. John Cush RheumNow
3 years 3 months ago
Survey of 3357 retired Olympians (45 yrs) shows same OA rates as 1735 gen population (41yrs) - #OA in 23% (knee 7.4%, hip, ankle). OA from Injury, age, obesity. Prior knee/hip injury increased OA rates significantly (aOR 1.51/4.03) https://t.co/JwaAidkGG1 https://t.co/30Zm7bDWUG
Poster Hall